Unknown

Dataset Information

0

Obinutuzumab: the more the merrier?


ABSTRACT: In this issue of Blood, Byrd et al present data from a randomized phase 2 study in which 78 previously untreated patients with chronic lymphocytic leukemia (CLL) received 8 cycles of either 1000 mg (the current standard dose) or 2000 mg of the anti-CD20 monoclonal antibody (mAb) obinutuzumab. The authors report a higher overall response rate with higher doses of obinutuzumab (67% vs 49%), but there was no significant difference in progression-free survival (PFS) between groups.

SUBMITTER: Burger JA 

PROVIDER: S-EPMC4705611 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Obinutuzumab: the more the merrier?

Burger Jan A JA  

Blood 20160101 1


In this issue of Blood, Byrd et al present data from a randomized phase 2 study in which 78 previously untreated patients with chronic lymphocytic leukemia (CLL) received 8 cycles of either 1000 mg (the current standard dose) or 2000 mg of the anti-CD20 monoclonal antibody (mAb) obinutuzumab. The authors report a higher overall response rate with higher doses of obinutuzumab (67% vs 49%), but there was no significant difference in progression-free survival (PFS) between groups. ...[more]

Similar Datasets

| S-EPMC3115238 | biostudies-literature
| S-EPMC4139733 | biostudies-literature
| S-EPMC7131891 | biostudies-literature
| S-EPMC4930077 | biostudies-literature
| S-EPMC5828441 | biostudies-literature
| S-EPMC1828074 | biostudies-literature
| S-EPMC5743493 | biostudies-literature
| S-EPMC8480196 | biostudies-literature
| S-EPMC5980409 | biostudies-literature
| S-EPMC6605648 | biostudies-literature